UCB SA agreed to pay $2 billion up front to acquire bispecific T-cell engager (TCE)-maker Candid Therapeutics Inc. and lead BCMA/CD3 TCE asset cizutamig (CND-106), continuing big pharma’s spree for China-made autoimmune assets in 2026.
As Celcuity Inc. awaits a U.S. FDA approval decision for gedatolisib in HER-positive, HER2-negative, PIK3CA wild-type advanced breast cancer, the company already is setting its sights on a supplemental NDA filing, based on a top-line readout of the multi-target PAM inhibitor in a PIK3CA-mutant breast cancer cohort.
Beone Medicines Ltd. gained an exclusive option to develop cancer immunotherapy HH-160 worldwide in a deal potentially worth more than $2 billion for Huahui Health Ltd., the developer of the trispecific antibody.
Sanyou Biopharmaceuticals Co. Ltd. has prepared and tested new antibody-drug conjugates (ADCs) comprising an antibody or antigen-binding fragment targeting tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) covalently linked to a cytotoxic agent through linker reported to be useful for the treatment of lung and stomach cancer.
Antibody-drug conjugates (ADCs) comprising an antibody targeting folate receptor α (FOLR1; FR-α) covalently linked to a cytotoxic drug have been described in a Shanghai Pharmaceuticals Holding Co. Ltd. patent and are reported to be potentially useful for the treatment of cancer.
Beijing Danatlas Pharmaceutical Technology Co. Ltd. has patented new crystalline salt forms of poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.
Hypersialylation in tumor cells is a potent mechanism of tumor immune evasion, pushing cancer progression by suppressing both innate and adaptive antitumor immunity. Shanghai Henlius Biotech Inc. has developed an engineered human sialidase enzyme fused to an anti-B7-H3 nanobody, named E-688 or HLX-316, that improves tumor desialylation, durability and efficacy both in vitro and in vivo, while maintaining a safe profile.
The MTHFD enzyme family is central to one-carbon metabolism, with MTHFD2 showing cancer-selective overexpression linked to poor prognosis. Emerging data also identify MTHFD1 as a therapeutic vulnerability in select tumors, supporting MTHFD-targeted drug development.
A month ahead of its June 5 PDUFA date, Arvinas Inc.’s vepdegestrant gained U.S. FDA approval for use in a specific type of advanced or metastatic breast cancer, becoming the first proteolysis targeting chimera, or PROTAC, drug to reach the market.
RSS
.webp?height=488&t=1670008838&width=650 "Acute myeloid leukemia")
